At the same time NLRP3 > 1.33 significantly discriminating between post-NAFLD hepatic fibrosis and non-fibrotic liver in patients with different body mass index and different metabolic risk factors with a sensitivity of 97.5%, specificity of 99.07%, PPV of 99.2%, NPV of 100% and accuracy of 98.3%. The gene discussed is NLRP3; the disease is metabolic dysfunction-associated steatotic liver disease.